Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability
Danish Firm Hoping For More From Migraine Drug
Feb 09 2022
•
By
Ayisha Sharma
Migraine Drug Vyepti Had Been Touted As Transformational For The Firm • Source: Alamy
More from Earnings
More from Business